Drug profile · INN
aducanumab
ADUHELM
aducanumab (ADUHELM) is a beta amyloid a4 protein binding agent.
Drug details — aducanumab
- Class
- Nervous system (N07)
- Route
- —
- Patents
- 0
- Programs
- 0
- Data quality
- 0.83
Quick answer
aducanumab (ADUHELM) is a beta amyloid a4 protein binding agent.
Key facts
Mechanism of action
Beta amyloid A4 protein binding agent
Primary target: Amyloid-beta precursor protein
Approval history
| Authority | Status | Date |
|---|---|---|
| EMA | application withdrawn | — |
Recent coverage
FDA Approves Aduhelm: Key Details on Biogen's Alzheimer's Drug
Aduhelm, recently approved by the FDA, represents a pivotal moment in Alzheimer's treatment, offering hope for patients and families affected by this devastating disease.
FDA Breakthrough Therapy Designations: Advancing Alzheimer's Drug Development
Learn how FDA Breakthrough Therapy Designations are transforming Alzheimer's drug development, focusing on innovative treatments like Aducanumab.
Related & competitor drugs
Frequently asked questions
What is aducanumab?
aducanumab (ADUHELM) is a beta amyloid a4 protein binding agent.
What is the brand name for aducanumab?
ADUHELM is a marketed brand name for aducanumab. Check FDA Drugs@FDA for the current US label holder and prescribing information.